8-K: 4D Molecular Therapeutics Secures $93.3M in Equity Offering

4D Molecular Therapeutics successfully closed an equity offering, raising approximately $93.3 million through the sale of common stock and pre-funded warrants.

Summary

• 4D Molecular Therapeutics, Inc. (FDMT) entered into an underwriting agreement on November 6, 2025, and closed an offering on November 7, 2025.
• The company issued and sold 8,385,809 shares of its common stock at an offering price of $10.51 per share.
• Additionally, 1,128,949 pre-funded warrants were sold at a price of $10.5099 per warrant, with an exercise price of $0.0001 per warrant.
• The underwriters purchased the common stock at $9.8794 per share and the pre-funded warrants at $9.8793 per warrant.
• Net proceeds from the offering totaled approximately $93.3 million, after deducting underwriting discounts, commissions, and estimated offering expenses.
• The offering was conducted under the company's registration statement on Form S-3, which became effective on August 15, 2023.
• Company directors and executive officers are subject to a lock-up agreement, restricting sales or transfers of common stock until January 6, 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A significant capital raise provides essential funding for operations and strategic initiatives, which is crucial for a biotech company. However, it also entails dilution for existing shareholders, which can be a negative factor.

Positives

• The company successfully raised approximately $93.3 million in net proceeds, significantly bolstering its financial position.
• The offering included pre-funded warrants, which can attract investors seeking to mitigate immediate dilution or manage tax implications, while still providing capital to the company.
• The common stock and warrant shares are expected to be listed on the Nasdaq Global Select Market, maintaining liquidity and market access.

Negatives

• The issuance of new common stock and pre-funded warrants will result in dilution for existing shareholders.
• The underwriting discounts and commissions, along with other offering expenses, reduced the gross proceeds by a notable amount.

Risks

• The company has agreed to indemnify the underwriters against certain liabilities, including those under the Securities Act of 1933, which represents a contingent financial obligation.
• The company's ability to perform its obligations under the underwriting agreement and consummate the transactions could be affected by a 'Material Adverse Effect' on its business, properties, financial position, or results of operations.
• Market conditions, including suspensions or limitations in trading on major exchanges or general financial, political, or economic crises, could make it impracticable or inadvisable to proceed with the offering or delivery of securities.

Future Outlook

The company intends to use the net proceeds from the offering in the manner specified in the Pricing Disclosure Package and the Prospectus under the caption 'Use of Proceeds'. The shares and warrant shares are expected to be listed on the Nasdaq Global Select Market.

Management Comments

• David Kirn, M.D., Chief Executive Officer, signed the 8-K filing.
• Ashoo Gupta, Vice President, Finance & Controller, signed the Underwriting Agreement.

Industry Context

This equity offering provides 4D Molecular Therapeutics with additional capital, which is crucial for biotechnology companies to fund ongoing research and development, clinical trials, and general corporate purposes. Such capital raises are common in the biotech sector to support long development cycles and high R&D costs, especially for companies listed on major exchanges like Nasdaq.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders:** Experience dilution due to the issuance of new shares and warrants, but the company's financial runway is extended, potentially supporting future growth and value creation.
• **Investors (new):** Gain the opportunity to invest in the company's common stock or pre-funded warrants at the offering price.
• **Company:** Receives substantial capital to fund its operations, research, and development, reducing immediate liquidity concerns.
• **Management/Directors:** Subject to lock-up agreements, restricting their ability to sell shares for a specified period, which can signal commitment to the company's long-term prospects.

Next Steps

• The company will list the newly issued shares and warrant shares on the Nasdaq Global Select Market.
• The company will utilize the net proceeds as outlined in its prospectus.

Key Dates

Keywords

Equity Offering, Common Stock, Pre-Funded Warrants, Capital Raise, Underwriting Agreement, SEC Filing, 4D Molecular Therapeutics, FDMT, Nasdaq